Adherence to long-term follow-up preventive practices in allogeneic hematopoietic cell transplantation survivors from North India.
LTFU care
adherence
allo-HCT
cardio-metabolic
Journal
Blood cell therapy
ISSN: 2432-7026
Titre abrégé: Blood Cell Ther
Pays: Japan
ID NLM: 9918333884906676
Informations de publication
Date de publication:
25 Aug 2022
25 Aug 2022
Historique:
received:
31
12
2021
accepted:
28
02
2022
entrez:
30
1
2023
pubmed:
31
1
2023
medline:
31
1
2023
Statut:
epublish
Résumé
There are existing international guidelines for long-term follow-up (LTFU) care of allogeneic hematopoietic cell transplantation (allo-HCT) survivors. However, implementing these guidelines represents a unique challenge in resource-challenged settings. This study aimed to evaluate adherence to recommended surveillance in allo-HCT survivors at an academic center in North India and study the incidence of late effects. This single-center, retrospective study analyzed records of allo-HCT recipients from 2016 to 2020. Survivors were screened in our LTFU clinic at day +100 and +365 using cardiometabolic parameters (screening for hypertension, dyslipidemia, hyperglycemia, 24-hour urine protein, thyroid function), pulmonary function test (PFT), bone mineral density (BMD), and initiation of revaccination. A total of 40/80 (50%) allo-HCT survivors were alive at a median of 888 days (IQR 515-1,306). The adherence to home-based screening parameters such as blood pressure and blood glucose was highest (>75%), followed by lab-based parameters (45-70%), and lowest for specialized tests such as PFT (<50%) at both day +100 and +365 time points. Adherence to the initiation of revaccination was only 67%. At least one cardiometabolic parameter was out of range in 55% and 63% of survivors at day +100 and +365, respectively. The adherence to recommended surveillance measures for allo-HCT survivors in an academic LTFU clinic at one year was only 75% overall. Cardiometabolic abnormalities were noted in more than half of the survivors. This study emphasizes the need for a structured LTFU clinic in all centers performing HCT.
Identifiants
pubmed: 36712553
doi: 10.31547/bct-2021-025
pmc: PMC9873420
doi:
Types de publication
Journal Article
Langues
eng
Pagination
83-86Informations de copyright
Copyright Ⓒ2022 Asia-Pacific Blood and Marrow Transplantation Group (APBMT).
Déclaration de conflit d'intérêts
The authors declare no conflict of interest. Disclosure forms provided by the authors are available on the website.
Références
Circulation. 2018 Jul 3;138(1):e1-e34
pubmed: 29794080
Bone Marrow Transplant. 2021 Nov;56(11):2820-2825
pubmed: 34274955
Support Care Cancer. 2022 Mar;30(3):2767-2776
pubmed: 34837539
Vaccine. 2018 Apr 12;36(16):2176-2180
pubmed: 29530635
Bone Marrow Transplant. 2012 Mar;47(3):337-41
pubmed: 22395764
J Clin Oncol. 2010 Feb 20;28(6):1011-6
pubmed: 20065176
Biol Blood Marrow Transplant. 2019 Dec;25(12):2322-2329
pubmed: 31071457
Biol Blood Marrow Transplant. 2011 Jul;17(7):995-1003
pubmed: 21145404
Biol Blood Marrow Transplant. 2018 Jun;24(6):1119-1124
pubmed: 29608957
Indian J Endocrinol Metab. 2014 Jul;18(4):449-54
pubmed: 25143898